A general approach to site-specific antibody drug conjugates
暂无分享,去创建一个
Peter G Schultz | Ying Sun | Eric Feyfant | Mauricio Leal | Feng Tian | Ying Sun | P. Schultz | E. Feyfant | Feng Tian | H. Gerber | P. Sapra | D. Ma | Hans-Peter Gerber | S. Biroc | Lioudmila Tchistiakova | J. Dijoseph | H. Cho | Puja Sapra | Yingchun Lu | Hon Tran | J. Pinkstaff | R. Dushin | L. Tchistiakova | Maureen M. Dougher | Anthony Manibusan | M. Leal | Yingchun Lu | Aaron Sellers | Hon Tran | Trung Phuong | Richard Barnett | Brad Hehli | Frank Song | Michael J DeGuzman | Semsi Ensari | Jason K Pinkstaff | Lorraine M Sullivan | Sandra L Biroc | Ho Cho | John DiJoseph | Maureen Dougher | Dangshe Ma | Russell Dushin | Anthony Manibusan | M. Dougher | F. Song | S. Ensari | L. M. Sullivan | Michael Deguzman | T. Phuong | R. Barnett | Aaron Sellers | Brad Hehli | Lioudmila Tchistiakova
[1] M. Sliwkowski,et al. Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer , 2010 .
[2] Kelvin H. Lee,et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line , 2011, Nature Biotechnology.
[3] H. Rugo,et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Yokoyama,et al. Adding l-lysine derivatives to the genetic code of mammalian cells with engineered pyrrolysyl-tRNA synthetases. , 2008, Biochemical and biophysical research communications.
[5] U. RajBhandary,et al. Complete set of orthogonal 21st aminoacyl-tRNA synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three different termination codons in an mRNA in mammalian cells. , 2004, Nucleic acids research.
[6] B. E. Kimmel,et al. Optimized clinical performance of growth hormone with an expanded genetic code , 2011, Proceedings of the National Academy of Sciences.
[7] I. Wistuba,et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. , 2011, Cancer research.
[8] Paul Polakis,et al. Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.
[9] E. Hamel,et al. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity. , 2000, Molecular pharmacology.
[10] Susan E. Cellitti,et al. Site-specific protein modifications through pyrroline-carboxy-lysine residues , 2011, Proceedings of the National Academy of Sciences.
[11] M. Sliwkowski,et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.
[12] C. J. O’Donnell,et al. Investigational antibody drug conjugates for solid tumors , 2011, Expert opinion on investigational drugs.
[13] Damon L. Meyer,et al. Contribution of linker stability to the activities of anticancer immunoconjugates. , 2008, Bioconjugate chemistry.
[14] P. Burke,et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. , 2013, Bioconjugate chemistry.
[15] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[16] John M Lambert,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.
[17] G. Frantz,et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. , 2009, Cancer research.
[18] K. Aldape,et al. A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.
[19] R. Abraham,et al. Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells , 2012, Molecular Cancer Therapeutics.
[20] N. Kedersha,et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] Paul Polakis,et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.
[22] Carolyn R Bertozzi,et al. Cu-free click cycloaddition reactions in chemical biology. , 2010, Chemical Society reviews.
[23] Laurent Ducry,et al. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.
[24] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[25] Peter G Schultz,et al. An Expanded Eukaryotic Genetic Code , 2003, Science.
[26] F. Wurm. Production of recombinant protein therapeutics in cultivated mammalian cells , 2004, Nature Biotechnology.
[27] Peter G Schultz,et al. Adding amino acids to the genetic repertoire. , 2005, Current opinion in chemical biology.
[28] M. Dorywalska,et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. , 2013, Chemistry & biology.
[29] P. Polakis. Arming antibodies for cancer therapy. , 2005, Current opinion in pharmacology.
[30] Peter G Schultz,et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.